Great Point Partners LLC
Great Point Partners LLC reported 42 holdings worth US$529M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Great Point Partners LLC reported 42 holdings worth US$529M as of Jun 30, 2026. Largest: Vor Biopharma Inc., Abivax Sa and Vera Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 42
- Value as reported
- US$529M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Vor Biopharma Inc. | 1.7M | US$31.3M | 5.9% |
| Abivax Sa | 204K | US$27.2M | 5.1% |
| Vera Therapeutics, Inc. | 601K | US$25.8M | 4.9% |
| Zura Bio Limited | 4.22M | US$24.9M | 4.7% |
| Alumis Inc. | 856K | US$24.1M | 4.6% |
| Definium Therapeutics, Inc. | 425K | US$20M | 3.8% |
| Annexon, Inc. | 3.5M | US$20M | 3.8% |
| Oruka Therapeutics, Inc. | 183K | US$17.4M | 3.3% |
| Sagimet Biosciences Inc. - Series A | 2.03M | US$15.7M | 3.0% |
| Contineum Therapeutics, Inc. | 921K | US$15.1M | 2.9% |
| Immix Biopharma, Inc. | 1.28M | US$13.2M | 2.5% |
| Climb Bio, Inc. | 1M | US$13M | 2.5% |
| Amylyx Pharmaceuticals, Inc. | 700K | US$12.6M | 2.4% |
| Nektar Therapeutics | 175K | US$12.2M | 2.3% |
| Neurogene Inc. | 352K | US$11.1M | 2.1% |
| Lb Pharmaceuticals Inc | 317K | US$10.3M | 1.9% |
| Opus Genetics, Inc. | 1.97M | US$8.1M | 1.5% |
| Eupraxia Pharmaceuticals, Inc. | 1.2M | US$7.93M | 1.5% |
| Bright Minds Biosciences Inc. | 110K | US$7.69M | 1.5% |
| Relmada Therapeutics, Inc. | 842K | US$5.83M | 1.1% |
| Jatt Ii Acquisition Corp | 500K | US$5.68M | 1.1% |
| Cullinan Therapeutics, Inc. | 300K | US$5.46M | 1.0% |
| Altimmune, Inc. | 1.74M | US$5.29M | 1.0% |
| Amanat Acquisition Corp | 500K | US$5.08M | 0.96% |
| Rezolute, Inc. | 952K | US$4.95M | 0.94% |
| Palisade Bio, Inc. | 2.28M | US$4.78M | 0.90% |
| Evommune, Inc. | 325K | US$4.32M | 0.82% |
| Enliven Therapeutics, Inc. | 70,000 | US$3.55M | 0.67% |
| Humacyte, Inc. | 3.75M | US$2.93M | 0.55% |
| Rein Therapeutics, Inc. | 2.58M | US$2.68M | 0.51% |
| Dbv Technologies Sa | 157K | US$2.57M | 0.49% |
| Promis Neurosciences Inc. | 86,150 | US$1.13M | 0.21% |
| Scynexis, Inc. | 0 | US$0 | 0.00% |
| Tenax Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Unicycive Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Zenas Biopharma, Inc. | 0 | US$0 | 0.00% |
| Apogee Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Avalo Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Compass Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Context Therapeutics Inc. | 0 | US$0 | 0.00% |
| Immunovant, Inc. | 0 | US$0 | 0.00% |
| Jade Biosciences, Inc. | 0 | US$0 | 0.00% |
| Kalvista Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related